XYLOBIOSE ia a natural product,and exhibited therapeutic potential for treating obesity which involved suppression of fat deposition and obesity-related metabolic disorders.

The mice were randomized into five groups: (a) a control group (Ctrl, n = 10) which received a diet of modified American Institute of Nutrition (AIN)-93G (17% of the calories are from fat); (b) a high fat diet (HFD)-induced obesity control group (HF, n = 13) which received a HFD comprised of 60% fat; (c) a xylose 15% group (Xylo 15) which received a HFD with 15% of the total sucrose replaced with d-xylose (n = 13); (d) an XYLOBIOSE 10% group (XYLOBIOSE 10, n = 13) which received a HFD with 10% of the total sucrose replaced by XYLOBIOSE; and (e) an XYLOBIOSE 15% group (XYLOBIOSE 15, n = 12) which received a HFD with 15% of the total sucrose replaced by XYLOBIOSE. Commercially available D-xylose was included as a positive control and was administered at a dose comparable to XYLOBIOSE. The mice were maintained on these diets according to their group for ten weeks prior to sacrifice. Body weight and food intake were measured twice a week.